Abcuro announces pre-clinical data on new immuno-oncology target
Member News
First in vivo validation of KLRG1 as a new cancer immunotherapy target
Related or similar articles
August 8, 2018
Harbour BioMed inks $350 million deal for rights to A167
USA-based Harbour BioMed has entered into an exclusive strategic partnership with China’s Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize A167
Member News
.webp)
April 25, 2024
Laboratory Space for Emerging Biotechs: Best Practices and Tips from Labshares
Labshares News
August 19, 2019
Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...
Member News